Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravenous autologous bone marrow-derived mesenchymal stem cells for chronic stroke (Phase II, STR01-05)
jRCT1090220330Phase 2Recruiting
- Sponsor
- Osamu Honmou, MD, PhD
- Start
- Feb 2018
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of autologous bone marrow derived mesenchymal stromal cells in stroke, sponsored by Osamu Honmou, MD, PhD. Primary endpoint: Primary: mRS improvement at 180 days. Started Feb 2018; status: recruiting.
02
Drugs
autologous bone marrow derived mesenchymal stromal cells
03
Conditions
stroke
Beyond the preview
Go deeper on jRCT1090220330.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1090220330.